Closing
Do GLP-1 receptor agonists improve quality of life & behaviour more than other treatments?
Mostly studied in type 2 & unspecified diabetes. Also asked versus placebo.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Doubtful. So far, no trial evidence yet.
NoUnsureYes
- Belief
- 0.25 (range 0.10–0.70)
- Trials for
- 0
- Trials against
- 0
- Inconclusive
- 5
Already under way
- SHAPE-ENDO (Strategic Hormonal Approach & Prehabilitation in Endometrial Cancer): An Open-Label, Pilot Randomized Clinical Trial Comparing Standard Immediate…NCT07462663 · not yet recruiting · started 2027
- A Randomized-Controlled Trial of Semaglutide for Patients With Chronic Low Back Pain and ObesityNCT07731256 · not yet recruiting · started 2027
- GLIDE-HF Registry: A Prospective, Single-Center, Observational Cohort of Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction, With…NCT07787936 · not yet recruiting · started 2027
- Evaluation of a Digital Treatment Tool in Combination With Obesity MedicationsNCT06836284 · recruiting · started 2026
- Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in YouthNCT06934655 · not yet recruiting · started 2026
The evidence so far
- Registered trials
- 289
- With posted results
- 78
- Published papers
- 8
Of 59 decided analyses: 14 favor glp-1 receptor agonists, 37 find no difference, 8 favor the comparator.
Papers
- Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study.Trial report · 2025
- Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.Trial report · 2020
- A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.Meta-analysis / systematic review · 2010
- Semaglutide for adults living with obesity.Meta-analysis / systematic review · 2025
- Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis.Meta-analysis / systematic review · 2021
- Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.Meta-analysis / systematic review · 2025
Trials
- A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-ARM, PARALLEL METHODOLOGY STUDY TO ASSESS THE EFFECT OF LIRAGLUTIDE ON FOOD INTAKE IN OBESE SUBJECTSNCT03041792 · 14 posted results
- A Single-centre, Randomised, Double-blind Two-period Cross-over Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With PlaceboNCT02079870 · 2 posted results
- GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and WeightNCT04779697 · 5 posted results
- Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related PrediabetesNCT05193578 · 2 posted results
- Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial DiseaseNCT04560998 · 2 posted results
- A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)NCT01720446 · 20 posted results
- A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 DiabetesNCT03987919 · 9 posted results
- Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist SettingNCT02963935 · 16 posted results